Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SLCO4C1 | Q6ZQN7 | 1/20 | 1.00 |
| ▸ | ATP1A1 | P05023 | 9/20 | 0.74 |
| ▸ | ATP1B1 | P05026 | 9/20 | 0.74 |
| ▸ | ATP1B2 | P14415 | 9/20 | 0.74 |
| ▸ | ATP1A2 | P50993 | 9/20 | 0.74 |
| ▸ | ATP1B3 | P54709 | 9/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.74 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.74 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Digoxigenin SCHEMBL13337910 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL8816469 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL4994463 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL21105 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL24012132 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL13362000 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL23827178 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL12841138 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL11077489 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL8816474 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139300-A1 | NUCLEIC ACID CONCATEMERS AND METHODS FOR STABILIZING AND/OR COMPACTING THE SAME | 10X GENOMICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260139301-A1 | CATALYTIC DE-CROSSLINKING OF SAMPLES FOR IN SITU ANALYSIS | 10X GENOMICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260139302-A1 | METHODS AND COMPOSITIONS FOR IN SITU ANALYSIS OF V(D)J SEQUENCES | 10X GENOMICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260132444-A1 | STABILIZATION AND/OR COMPACTION OF NUCLEIC ACID MOLECULES | 10X GENOMICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4741513-A2 | METHODS AND COMPOSITIONS FOR SYNCHRONIZING REACTIONS IN SITU | 10X Genomics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260125747-A1 | PROBES COMPRISING A SPLIT BARCODE REGION AND METHODS OF USE | 10X GENOMICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4573210-B1 | METHOD FOR ANALYSING GENE EXPRESSION IN CELLS IN A PELLET | 10X GENOMICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260117287-A1 | COMPOSITIONS AND METHODS FOR TARGETED MASKING OF AUTOFLUORESCENCE | 10X GENOMICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4370896-B1 | METHODS FOR PREPARING POLYMERIZED MATRIX WITH CONTROLLABLE THICKNESS | 10X GENOMICS INC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4733410-A2 | MULTIPLE READOUT SIGNALS FOR ANALYZING A SAMPLE | 10X Genomics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20220282313-A1 | CHEMICAL COMPOSITIONS AND USES THEREOF | BRUKER SPATIAL BIOLOGY, INC. | 2022-09-08 | — | — | US | disclosed |
| EP-4045887-A1 | CLINICAL- AND INDUSTRIAL-SCALE INTACT-TISSUE SEQUENCING | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022159474-A1 | METHODS AND COMPOSITIONS FOR INTERNALLY CONTROLLED IN SITU ASSAYS | 10X GENOMICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220228200-A1 | METHODS AND COMPOSITIONS FOR INTERNALLY CONTROLLED IN SITU ASSAYS | 10X GENOMICS, INC. | 2022-07-21 | — | — | US | disclosed |
| EP-4029952-A1 | ENZYME- AND AMPLIFICATION-FREE SEQUENCING | Nanostring Technologies, Inc (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220213532-A1 | CHEMICAL COMPOSITIONS AND METHODS OF USING SAME | BRUKER SPATIAL BIOLOGY, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220162694-A1 | DNA ARRAY | COMPLETE GENOMICS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220136049-A1 | SEQUENCE ANALYSIS USING META-STABLE NUCLEIC ACID MOLECULES | 10X GENOMICS, INC. | 2022-05-05 | — | — | US | disclosed |
| WO-2022060967-A1 | CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME | NANOSTRING TECHNOLOGIES, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-11279969-B2 | Chemical compositions and methods of using same | NANOSTRING TECHNOLOGIES, INC. (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139300-A1 | NUCLEIC ACID CONCATEMERS AND METHODS FOR STABILIZING AND/OR COMPACTING THE SAME | INCENP, SLIRP, SMCHD1 | TP53 247/4885PAX8 289/4885LMNA 126/4885 |
| US-20260139301-A1 | CATALYTIC DE-CROSSLINKING OF SAMPLES FOR IN SITU ANALYSIS | RNGTT, NSUN2, POLL | TP53 2961/4885PAX8 1640/4885LMNA 257/4885 |
| US-20260117287-A1 | COMPOSITIONS AND METHODS FOR TARGETED MASKING OF AUTOFLUORESCENCE | FABP3, HNRNPM, B2M | TP53 72/4885PAX8 1149/4885LMNA 211/4885 |
| US-20260132444-A1 | STABILIZATION AND/OR COMPACTION OF NUCLEIC ACID MOLECULES | SLIRP, SMCHD1, INCENP | TP53 519/4885PAX8 514/4885LMNA 40/4885 |
| US-20260139302-A1 | METHODS AND COMPOSITIONS FOR IN SITU ANALYSIS OF V(D)J SEQUENCES | POLL, VSIR, BCR | TP53 767/4885PAX8 496/4885LMNA 1216/4885 |
| US-20260125747-A1 | PROBES COMPRISING A SPLIT BARCODE REGION AND METHODS OF USE | LIG1, LIG4, LIG3 | TP53 649/4885PAX8 482/4885LMNA 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.